Valuation: ARS Pharmaceuticals, Inc.

Market Cap 532M 462M 433M 396M 747M 50.7B 757M 5.06B 1.99B 25.33B 2B 1.96B 84.32B P/E 2026 *
-3.01x
P/E 2027 * -5.57x
Enterprise Value 532M 462M 433M 396M 747M 50.7B 757M 5.06B 1.99B 25.33B 2B 1.96B 84.32B EV / Sales 2026 *
3.81x
EV / Sales 2027 * 2.17x
Free-Float
83.79%
Yield 2026 *
-
Yield 2027 * -
1 day+3.54%
1 week-1.42%
Current month+8.19%
1 month-33.37%
3 months-40.19%
6 months-44.67%
Current year-52.36%
1 week 4.91
Extreme 4.9102
5.6
1 month 4.91
Extreme 4.9102
8.53
Current year 4.91
Extreme 4.9102
13.15
1 year 4.91
Extreme 4.9102
18
3 years 2.55
Extreme 2.55
18.9
5 years 2.55
Extreme 2.55
18.9
10 years 2.55
Extreme 2.55
18.9
Manager TitleAgeSince
Chief Executive Officer 53 06/07/2026
Chief Tech/Sci/R&D Officer - 04/08/2015
Director of Finance/CFO 57 31/01/2022
Director TitleAgeSince
Chairman 56 07/11/2022
Director/Board Member 55 31/07/2021
Director/Board Member 56 30/06/2017
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Free

Chief Executive Officer

898,456 0.9048%
24/06/26 Free

Director

30,000 0.0302%
02/01/26 Free

General Counsel

240,000 0.2428%
Change 5-day change 1-year change 3-year change Capi.($)
+3.54%-1.42%-69.13%-19.62% 532M
+0.93%-1.43%+1.61%+14.93% 48.57B
+0.26%+2.93%+439.43%+567.38% 41.95B
-1.53%-2.25%+30.95%+5.99% 38.85B
+0.69%+2.40%+10.48%+75.87% 37.24B
+2.47%+8.33%+15.16%+48.37% 30.67B
-0.47%+1.16%+35.93%+124.67% 16.41B
+2.31%-0.49% - - 16.1B
+0.29%+1.81%+4.92%+18.60% 13.97B
-1.43%-2.63%+3.70%-35.93% 12.62B
Average +0.70%-1.08%+52.56%+88.92% 25.69B
Weighted average by Cap. +0.43%+0.38%+88.19%+128.35%

Financials

2026 *2027 *
Net sales 140M 121M 114M 104M 196M 13.32B 199M 1.33B 522M 6.66B 525M 514M 22.15B 246M 213M 200M 183M 345M 23.41B 349M 2.34B 917M 11.7B 923M 903M 38.93B
Net income -178M -154M -144M -132M -249M -16.93B -253M -1.69B -663M -8.46B -667M -653M -28.15B -97.73M -84.81M -79.41M -72.64M -137M -9.31B -139M -929M -365M -4.65B -367M -359M -15.48B
Net Debt - -
Logo ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.
Employees
157
Date Price Change Volume
06/08/26 US$5.550 +3.54% 1,264,269
05/08/26 US$5.360 +0.75% 2,542,539
04/08/26 US$5.320 -2.56% 1,931,422
03/08/26 US$5.460 +6.43% 2,143,695
31/07/26 US$5.130 -8.88% 2,083,381
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.360USD
Average target price
26.75USD
Spread / Average Target
+399.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRY Stock